Helius Med Technolog (HSDT) 0.7320 $HSDT U.S. Army and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Helius Med Technolog (HSDT) 0.7320 $HSDT

U.S. Army and Helius Medical Technologies Announce Launch of Phase 3 Traumatic Brain Injury Clinical Trial
Business Wire - Tue Aug 11, 9:15AM CDT
Helius Medical Technologies (CSE: HSM) (OTCQB: HSDT) ("Helius", or the "Company" and the U.S. Army Medical Research and Materiel Command ("USAMRMC" announce the launch of a Phase 3 clinical trial to investigate the safety and effectiveness of the Portable Neuromodulation Stimulator ("PoNS(TM)" 4.0 device, a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury ("mTBI". The trial is intended to serve as the basis for seeking Canadian and U.S. marketing approvals of the PoNS(TM). The PoNS(TM) is an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue.

Helius Medical Technologies Issues Corporate Update
TheNewswire.ca - Fri Aug 07, 8:15AM CDT
(via Thenewswire.ca)

Helius Medical Technologies Announces Closing of Cad $330,738 Non-Brokered Private Placement
TheNewswire.ca - Fri Jul 17, 4:31PM CDT
(via Thenewswire.ca)

Helius Medical Technologies Inventors Granted US Patent No. 9,072,889
Business Wire - Wed Jul 15, 10:04AM CDT
Helius Medical Technologies, Inc. (CSE:HSM)(OTCQB:HSDT) ("Helius", or the "Company" announced today that the US Patent and Trademark Office ("USPTO" issued the Company its first patent related to the design of the new Portable Neuromodulation Stimulation ("PoNS(TM)" 4.0 device. The PoNS(TM) is currently being studied in the United States for the treatment of chronic balance symptoms caused by mild-moderate Traumatic Brain Injury ("TBI" and in Canada for chronic balance and gait symptoms caused by Multiple Sclerosis.

Helius Medical Technologies Inventors' Granted Us Patent No. 9,072,889, a Systems for Providing Non-Invasive Neurorehabilitation of a Patienta
TheNewswire.ca - Wed Jul 15, 8:15AM CDT
(via Thenewswire.ca)

U.S. Army and Helius Medical Technologies Execute Sole Source Contract for the PoNS(TM) Device Testing and Development
Business Wire - Tue Jul 07, 9:15AM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company" announced that NeuroHabilitation Corporation ("NHC", a division of Helius, successfully executed a sole source cost sharing contract with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract will support Helius' registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)), a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury (mTBI).

Helius Medical Technologies Announces Closing of CAD $875,558 Non-Brokered Private Placement
TheNewswire.ca - Fri Jun 26, 5:30PM CDT
(via Thenewswire.ca)

Helius Medical Technologies Announces Clinical Device Readiness for PoNS(TM) 4.0
Business Wire - Thu Jun 25, 11:21AM CDT
Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("Helius" is pleased to announce that it has successfully released the first clinical version of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device. The PoNS 4.0 device is manufactured by Ximedica LLC and will be used in Helius' registrational clinical trial, to investigate its safety and effectiveness for the treatment of balance disorder caused by traumatic brain injury.

Helius Medical Technologies Announces Clinical Device Readiness for PoNS (tm) 4.0
TheNewswire.ca - Thu Jun 25, 8:19AM CDT
(via Thenewswire.ca)

Helius Medical Technologies Amends and Re-files Historical Financial Statements and Material Change Report
ACCESSWIRE - Thu Jun 04, 7:12PM CDT
NEWTOWN, PA / ACCESSWIRE / June 4, 2015 / Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("HMT", or the "Company" - As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.

Helius Medical Technologies Achieves Full Enrollment in Canadian MS Feasibility Study
Business Wire - Wed May 20, 9:15AM CDT
Helius Medical Technologies ("Helius", "HMT", or the "Company" announced that it has achieved full enrollment for its Multiple Sclerosis pilot clinical trial at the Montreal Neurological Institute. The trial, "Examining the efficacy of non-invasive neuromodulation in reducing symptoms of Multiple Sclerosis," launched in February 2015, is a 14-subject, blinded feasibility study investigating Helius' Portable Neuromodulation Stimulator (PoNS(TM)) and physiotherapy protocol on the rehabilitation of balance and gait symptoms in subjects with Multiple Sclerosis.

Helius Medical Technologies Announces Closing of Cad $2,208,110 Non-Brokered Private Placement
ACCESSWIRE - Thu Apr 30, 5:07PM CDT
NEWTOWN, PA / ACCESSWIRE / April 30, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company" is pleased to announce that it has closed a non-brokered private placement (the "Financing" raising gross proceeds of CAD $2,208,110 (approximately USD $1,825,937) by the issuance of 849,273 units (each a "Unit" at a price of CAD $2.60 per Unit (USD $2.15 per Unit). Each Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Warrant". Each whole Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of approximately CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.

Helius Medical Technologies Inventors' Granted US Patent No. 14/341,141
Business Wire - Tue Apr 14, 9:20AM CDT
Helius Medical Technologies, Inc. (CSE:HSM)(OTCQB:HSDT) ("Helius", or the "Company" announced today that the US Patent and Trademark Office (USPTO) issued a third patent related to its Portable Neuromodulation Stimulation (PoNS(TM)) device and the associated therapeutic modality. U.S. Patent No. 14/341,141 "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function", issued on April 10, 2015, is directed to a non-invasive neuromodulation therapy that uses intraoral cutaneous stimulation in conjunction with cognitive exercise.

Helius Medical Technologies to Start Its Registrational Clinical Trial
Business Wire - Mon Apr 13, 12:04PM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" is pleased to announce that it recently met with the US Food and Drug Administration ("FDA" or the "Agency" as part of the Agency's pre-submission (pre-sub) process regarding Helius's protocol for its double-blind, randomized, sham-controlled study of the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device for cranial nerve noninvasive neuromodulation (CN-NINM) training in subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 17

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 0

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 0

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 39

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 51

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights on E Split Corp. Class A Distribution for Shareholders

Updated Category News Views 147

E Split Corp. Class A Distribution Announcement Toronto-based E Split Corp. (TSX: ENS) is thrilled to share important news with its Class A shareholders regarding the upcoming distribution for October. This is a significant update for investors who are keen on dividend payments made by this dynamic fund. Details of the Distribution This distribution signals the company's...

Continue Reading
Aberdeen Investments: Recent Distribution Insights for Shares

Updated Category News Views 187

Understanding Distribution Payments from Aberdeen Investments Aberdeen Investments U.S. Closed-End Funds, including stocks like ASGI, have announced significant updates regarding their distribution payments. These distributions are crucial for investors as they represent a return on their investments. Released on a recent date, the Funds paid these distributions per share...

Continue Reading
Nuvini Group's Impressive 2025 Financial Performance Review

Updated Category News Views 191

Nuvini Group Report Highlights Growth in 2025 Nuvini Group Limited (NASDAQ: NVNI) is making waves with its impressive financial results for the first half of 2025. This Brazilian venture is recognized as a premier acquirer and operator of business-to-business (B2B) software as a service (SaaS) companies. The company has demonstrated a significant increase in cash flow...

Continue Reading
Exciting Housing Announcement: Key Insights for Communities

Updated Category News Views 156

Anticipating New Housing Developments Media outlets are set to cover an important housing announcement with significant implications for local communities. This event highlights the collaboration between government officials and community leaders focused on addressing housing needs and enhancing infrastructure in various regions. Key Officials Present at the Event The...

Continue Reading
Investors Rally Against Edwards Lifesciences After Losses

Updated Category News Views 72

Edwards Lifesciences Faces Investor Backlash Amidst significant financial turmoil, Edwards Lifesciences Corporation (NYSE: EW) is grappling with a class action lawsuit initiated by concerned investors. This situation emerged after the company witnessed a staggering loss exceeding $16 billion in market capitalization. Investors are understandably anxious as they reflect on...

Continue Reading